About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 692097, 15 pages
http://dx.doi.org/10.1155/2010/692097
Review Article

Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience

1Department of Immunology and Transfusion Medicine, Haukeland University Hospital, 5021 Bergen, Norway
2Department of Medicine, Section for Hematology, Haukeland University Hospital, 5021 Bergen, Norway
3Institute of Internal Medicine, University of Bergen, Haukeland University Hospital, 5021 Bergen, Norway

Received 30 November 2009; Accepted 20 March 2010

Academic Editor: Zhengguo Xiao

Copyright © 2010 Knut Liseth et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Keilholz, A. Letsch, A. Busse, et al., “A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS,” Blood, vol. 113, no. 26, pp. 6541–6548, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. J. J. Molldrem, P. P. Lee, C. Wang, et al., “Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia,” Nature Medicine, vol. 6, no. 9, pp. 1018–1023, 2000. View at Publisher · View at Google Scholar · View at PubMed
  3. Y. Oka, A. Tsuboi, T. Taguchi, et al., “Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13885–13890, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. A. Smith, F. Wisloff, and D. Samson, “Guidelines on the diagnosis and management of multiple myeloma 2005,” British Journal of Haematology, vol. 132, no. 4, pp. 410–451, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. K. Liseth, J. F. Abrahamsen, R. Ekanger, I. Nesthus, and M. S. Sjo, “Survival after high-dose therapy with autologous stem cell support,” Tidsskrift for den Norske Laegeforening, vol. 124, no. 10, pp. 1374–1375, 2004.
  6. L. F. Porrata, M. R. Litzow, A. Tefferi, et al., “Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia,” Leukemia, vol. 16, no. 7, pp. 1311–1318, 2002. View at Publisher · View at Google Scholar · View at PubMed
  7. L. F. Porrata and S. N. Markovic, “Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation,” Clinical and Experimental Medicine, vol. 4, no. 2, pp. 78–85, 2004. View at Publisher · View at Google Scholar
  8. L. F. Porrata, M. A. Gertz, D. J. Inwards, et al., “Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma,” Blood, vol. 98, no. 3, pp. 579–585, 2001. View at Publisher · View at Google Scholar
  9. R. Parkman, G. Cohen, S. L. Carter, et al., “Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation,” Biology of Blood and Marrow Transplantation, vol. 12, no. 9, pp. 919–927, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. D. H. Kim, S. K. Sohn, D. I. Won, N. Y. Lee, J. S. Suh, and K. B. Lee, “Rapid helper T-cell recovery above 200 × 106 /l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 37, no. 12, pp. 1119–1128, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. E. Ersvær, J.-Y. Zhang, E. McCormack, et al., “Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients,” European Journal of Haematology, vol. 79, no. 3, pp. 210–225, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. D. Behl, L. F. Porrata, S. N. Markovic, et al., “Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia,” Leukemia, vol. 20, no. 1, pp. 29–34, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. O. Bruserud, E. Ulvestad, S. Berentsen, J. Bergheim, and I. Nesthus, “T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation,” Scandinavian Journal of Immunology, vol. 47, no. 1, pp. 54–62, 1998. View at Publisher · View at Google Scholar
  14. O. Bruserud, “Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells,” International Journal of Immunopharmacology, vol. 22, no. 1, pp. 69–81, 2000. View at Publisher · View at Google Scholar
  15. E. Ersvær, P. Hampson, O. Wendelbo, J. M. Lord, B. T. Gjertsen, and O. Bruserud, “Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex,” Hematology, vol. 12, no. 3, pp. 199–207, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. E. Ersvær, P. Hampson, K. Hatfield, et al., “T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-γ that can be further increased by a novel protein kinase C agonist PEP005,” Cancer Immunology, Immunotherapy, vol. 56, no. 6, pp. 913–925, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. A. M. Olsnes, A. Ryningen, E. Ersvær, and O. Bruserud, “In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22,” Journal of Interferon and Cytokine Research, vol. 28, no. 5, pp. 297–310, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. A. M. Olsnes, E. Ersvær, A. Ryningen, and O. Bruserud, “Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors,” Hematology, vol. 13, no. 6, pp. 329–332, 2008. View at Publisher · View at Google Scholar · View at PubMed
  19. C. L. Mackall, T. A. Fleisher, M. R. Brown, et al., “Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy,” Blood, vol. 89, no. 10, pp. 3700–3707, 1997.
  20. G. M. Crooks, K. Weinberg, and C. Mackall, “Immune reconstitution: from stem cells to lymphocytes,” Biology of Blood and Marrow Transplantation, vol. 12, supplement 1, pp. 42–46, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. J. C. Karl and C. L. Mackall, “Cancer therapy-induced immune modulation,” Cancer Chemotherapy and Biological Response Modifiers, vol. 22, pp. 325–341, 2005.
  22. C. L. Mackall and L. J. Helman, “High-dose chemotherapy for rhabdomyosarcoma: where do we go from here,” Journal of Pediatric Hematology and Oncology, vol. 23, no. 5, pp. 266–267, 2001. View at Publisher · View at Google Scholar
  23. C. L. Mackall, “T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review,” Stem Cells, vol. 18, no. 1, pp. 10–18, 2000.
  24. E. Ashihara, C. Shimazaki, N. Yamagata, et al., “Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis,” Bone Marrow Transplantation, vol. 13, no. 4, pp. 377–381, 1994.
  25. M. Jimenez, G. Ercilla, and C. Martinez, “Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens,” Leukemia, vol. 21, no. 8, pp. 1628–1637, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. O. Bruserud and A. O. Kittang, “The chemokine system in experimental and clinical hematology,” Current Topics in Microbiology and Immunology. In press.
  27. M. L. Salem and D. J. Cole, “Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination,” Cancer Immunology, Immunotherapy, vol. 59, no. 3, pp. 341–353, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. M. A. Socinski, S. A. Cannistra, A. Elias, K. H. Antman, L. Schnipper, and J. D. Griffin, “Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man,” The Lancet, vol. 1, no. 8596, pp. 1194–1198, 1988.
  29. M. A. Socinski, S. A. Cannistra, R. Sullivan, et al., “Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo,” Blood, vol. 72, no. 2, pp. 691–697, 1988.
  30. E. Vellenga, M. van Agthoven, A. J. Croockewit, et al., “Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study,” British Journal of Haematology, vol. 114, no. 2, pp. 319–326, 2001. View at Publisher · View at Google Scholar
  31. J. M. Vose, G. Sharp, W. C. Chan, et al., “Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease,” Journal of Clinical Oncology, vol. 20, no. 9, pp. 2344–2352, 2002. View at Publisher · View at Google Scholar
  32. M. Körbling and P. Anderlini, “Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?” Blood, vol. 98, no. 10, pp. 2900–2908, 2001. View at Publisher · View at Google Scholar
  33. T. J. Smith, J. Khatcheressian, G. H. Lyman, et al., “2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. J.-P. Levesque, Y. Takamatsu, S. K. Nilsson, D. N. Haylock, and P. J. Simmons, “Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor,” Blood, vol. 98, no. 5, pp. 1289–1297, 2001. View at Publisher · View at Google Scholar
  35. M. Korbling, Y. O. Huh, A. Durett, et al., “Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1(dim)) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease,” Blood, vol. 86, no. 7, pp. 2842–2848, 1995.
  36. E. A. Copelan, S. K. Ceselski, S. A. Ezzone, et al., “Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 759–765, 1997.
  37. O. N. Koc, S. L. Gerson, B. W. Cooper, et al., “Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF,” Journal of Clinical Oncology, vol. 18, no. 9, pp. 1824–1830, 2000.
  38. A. Isidori, M. Tani, F. Bonifazi, et al., “Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients,” Haematologica, vol. 90, no. 2, pp. 225–231, 2005.
  39. J. A. Glaspy, E. J. Shpall, C. F. LeMaistre, et al., “Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients,” Blood, vol. 90, no. 8, pp. 2939–2951, 1997.
  40. E. J. Shpall, “The utilization of cytokines in stem cell mobilization strategies,” Bone Marrow Transplantation, vol. 23, supplement 2, pp. S13–S19, 1999.
  41. G. Calandra, J. McCarty, J. McGuirk, et al., “AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data,” Bone Marrow Transplantation, vol. 41, no. 4, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. N. Flomenberg, S. M. Devine, J. F. DiPersio, et al., “The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone,” Blood, vol. 106, no. 5, pp. 1867–1874, 2005. View at Publisher · View at Google Scholar · View at PubMed
  43. G. Calandra, G. Bridger, and S. Fricker, “CXCR4 in clinical hematology,” Current Topics in Microbiology and Immunology. In press.
  44. W. Bensinger, F. Appelbaum, S. Rowley, et al., “Factors that influence collection and engraftment of autologous peripheral-blood stem cells,” Journal of Clinical Oncology, vol. 13, no. 10, pp. 2547–2555, 1995.
  45. J. M. Goldman, K. H. Th'ng, and D. S. Park, “Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation,” British Journal of Haematology, vol. 40, no. 2, pp. 185–195, 1978.
  46. D. English, “Freezing hematopoietic stem cells,” Journal of Hematotherapy and Stem Cell Research, vol. 9, no. 2, pp. 123–125, 2000. View at Publisher · View at Google Scholar
  47. C. Scheinkonig, S. Kappicht, H.-J. Kolb, and M. Schleuning, “Adoption of long-term cultures to evaluate the cryoprotective potential of trehalose for freezing hematopoietic stem cells,” Bone Marrow Transplantation, vol. 34, no. 6, pp. 531–536, 2004. View at Publisher · View at Google Scholar · View at PubMed
  48. K. Liseth, J. F. Abrahamsen, S. Bjorsvik, K. Grottebo, and O. Bruserud, “The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft,” Cytotherapy, vol. 7, no. 4, pp. 328–333, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Vela-Ojeda, M. A. Garcia-Ruiz Esparza, E. Reyes-Maldonado, et al., “Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation,” Annals of Hematology, vol. 85, no. 2, pp. 113–120, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. K. Liseth, E. Ersvær, J. F. Abrahamsen, I. Nesthus, A. Ryningen, and O. Bruserud, “Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells,” Transfusion, vol. 49, no. 8, pp. 1709–1719, 2009. View at Publisher · View at Google Scholar · View at PubMed
  51. H. Unsoeld and H. Pircher, “Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7,” Journal of Virology, vol. 79, no. 7, pp. 4510–4513, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. F. Sallusto, D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia, “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, vol. 401, no. 6754, pp. 708–712, 1999. View at Publisher · View at Google Scholar · View at PubMed
  53. M. A. Curotto de Lafaille and J. J. Lafaille, “Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?” Immunity, vol. 30, no. 5, pp. 626–635, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. J. Yu, H. C. Mao, M. Wei, et al., “CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets,” Blood, vol. 115, no. 2, pp. 274–281, 2010. View at Publisher · View at Google Scholar · View at PubMed
  55. J. Rolin, K. L. Sand, E. Knudsen, and A. A. Maghazachi, “FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release,” Cancer Immunology, Immunotherapy, vol. 59, no. 4, pp. 575–586, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. A. A. Maghazachi, “Role of chemokines in the biology of natural killer cells,” Current Topics in Microbiology and Immunology. In press.
  57. S. Miltenyi, “CD34+ selection: the basic component for graft engineering,” Oncologist, vol. 2, no. 6, pp. 410–413, 1997.
  58. K. L. Knutson and M. L. Disis, “Tumor antigen-specific T helper cells in cancer immunity and immunotherapy,” Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 721–728, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. E. H. Warren, N. Fujii, Y. Akatsuka, et al., “Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens,” Blood, vol. 115, no. 19, pp. 3869–3878, 2010.
  60. L. F. Porrata, M. R. Litzow, and S. N. Markovic, “Immune reconstitution after autologous hematopoietic stem cell transplantation,” Mayo Clinic Proceedings, vol. 76, no. 4, pp. 407–412, 2001.
  61. T. Guillaume, D. B. Rubinstein, and M. Symann, “Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation,” Blood, vol. 92, no. 5, pp. 1471–1490, 1998.
  62. I. Yakoub-Agha, P. Saule, L. Magro, et al., “Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse,” Biology of Blood and Marrow Transplantation, vol. 15, no. 4, pp. 496–504, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. M. Cavazzana-Calvo, I. Andre-Schmutz, L. Dal Cortivo, B. Neven, S. Hacein-Bey-Abina, and A. Fischer, “Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress,” Current Opinion in Immunology, vol. 21, no. 5, pp. 544–548, 2009. View at Publisher · View at Google Scholar · View at PubMed
  64. J. E. Talmadge, E. Reed, K. Ino, et al., “Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow,” Bone Marrow Transplantation, vol. 19, no. 2, pp. 161–172, 1997.
  65. C. L. Mackall, D. Stein, T. A. Fleisher, et al., “Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults,” Blood, vol. 96, no. 2, pp. 754–762, 2000.
  66. S. Cayeux, S. Meuer, A. Pezzutto, et al., “T-cell ontogeny after autologous bone marrow transplantation: failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogeneous IL-2,” Blood, vol. 74, no. 6, pp. 2270–2277, 1989.
  67. A. Nolte, R. Buhmann, C. Straka, B. Emmerich, and M. Hallek, “Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation,” Bone Marrow Transplantation, vol. 21, no. 9, pp. 909–916, 1998.
  68. R. A. Miller, J. Daley, R. Ghalie, and H. Kaizer, “Clonal analysis of T-cell deficiencies in autotransplant recipients,” Blood, vol. 77, no. 8, pp. 1845–1850, 1991.
  69. P. Dreger, K. Viehmann, N. von Neuhoff, et al., “Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery,” Bone Marrow Transplantation, vol. 24, no. 2, pp. 153–161, 1999.
  70. A. Galy, S. Rudraraju, R. Baynes, and J. Klein, “Recovery of lymphocyte and dendritic cell subsets after autologous CD34+ cell transplantation,” Bone Marrow Transplantation, vol. 25, no. 12, pp. 1249–1255, 2000.
  71. J. Loeffler, M. Ok, O. C. Morton, M. Mezger, and H. Einsele, “Genetic polymorphisms in the cytokine and chemokine system: Their possible importance in allogeneic stem cell transplantation,” Current Topics in Microbiology and Immunology. In press.
  72. J. Storek, S. Ferrara, N. Ku, J. V. Giorgi, R. E. Champlin, and A. Saxon, “B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny?” Bone Marrow Transplantation, vol. 12, no. 4, pp. 387–398, 1993.
  73. G. H. Marin, M. C. Mendez, M. E. Menna, et al., “Immune recovery after bone marrow and peripheral blood stem cells transplantation,” Transplantation Proceedings, vol. 31, no. 6, pp. 2582–2584, 1999. View at Publisher · View at Google Scholar
  74. J. Tanaka, M. Asaka, and M. Imamura, “Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia,” International Journal of Hematology, vol. 81, no. 1, pp. 6–12, 2005. View at Publisher · View at Google Scholar
  75. J. Rolin, K. L. Sand, E. Knudsen, and A. A. Maghazachi, “FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release,” Cancer Immunology, Immunotherapy, vol. 59, no. 4, pp. 575–586, 2010. View at Publisher · View at Google Scholar · View at PubMed
  76. G. Weber, J. Karbach, S. Kuci, et al., “WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation,” Leukemia, vol. 23, no. 9, pp. 1634–1642, 2009.
  77. F. O. Smith, W. H. Raskind, P. J. Fialkow, and I. D. Bernstein, “Cellular biology of acute myelogenous leukemia,” Journal of Pediatric Hematology and Oncology, vol. 17, no. 2, pp. 113–122, 1995.
  78. T. Dao and D. A. Scheinberg, “Peptide vaccines for myeloid leukaemias,” Best Practice and Research: Clinical Haematology, vol. 21, no. 3, pp. 391–404, 2008. View at Publisher · View at Google Scholar · View at PubMed
  79. C. Scheibenbogen, A. Letsch, E. Thiel, et al., “CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia,” Blood, vol. 100, no. 6, pp. 2132–2137, 2002. View at Publisher · View at Google Scholar · View at PubMed
  80. K. Rezvani, “PR1 vaccination in myeloid malignancies,” Expert Review of Vaccines, vol. 7, no. 7, pp. 867–875, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. K. Rezvani, A. S. M. Yong, S. Mielke, et al., “Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies,” Blood, vol. 111, no. 1, pp. 236–242, 2008. View at Publisher · View at Google Scholar · View at PubMed
  82. E. L. J. M. Smits, Z. N. Berneman, and V. F. I. Van Tendeloo, “Immunotherapy of acute myeloid leukemia: current approaches,” Oncologist, vol. 14, no. 3, pp. 240–252, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. J. Greiner, M. Schmitt, L. Li, et al., “Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches,” Blood, vol. 108, no. 13, pp. 4109–4117, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. Y. Oka, A. Tsuboi, T. Taguchi, et al., “Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13885–13890, 2004. View at Publisher · View at Google Scholar · View at PubMed
  85. M. Schmitt, A. Schmitt, M. T. Rojewski, et al., “RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses,” Blood, vol. 111, no. 3, pp. 1357–1365, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. L. Li, K. Giannopoulos, P. Reinhardt, et al., “Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts,” International Journal of Oncology, vol. 28, no. 4, pp. 855–861, 2006.
  87. J.-J. Lee, H. Kook, M.-S. Park, et al., “Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation,” Journal of Clinical Apheresis, vol. 19, no. 2, pp. 66–70, 2004. View at Publisher · View at Google Scholar · View at PubMed
  88. T. Osada, T. Clay, A. Hobeika, H. K. Lyerly, and M. A. Morse, “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity,” Cancer Immunology, Immunotherapy, vol. 55, no. 9, pp. 1122–1131, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. O. Bruserud, B. T. Gjertsen, B. Foss, and T.-S. Huang, “New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells—The present use in experimental studies and the possible importance for future therapeutic approaches,” Stem Cells, vol. 19, no. 1, pp. 1–11, 2001.
  90. A. M. Olsnes, A. Ryningen, E. Ersvær, and O. Bruserud, “In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22,” Journal of Interferon and Cytokine Research, vol. 28, no. 5, pp. 297–310, 2008. View at Publisher · View at Google Scholar · View at PubMed
  91. K. Giannopoulos, L. Li, A. Bojarska-Junak, et al., “Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia,” International Journal of Oncology, vol. 29, no. 1, pp. 95–103, 2006.
  92. C. J. M. Melief, “Cancer immunotherapy by dendritic cells,” Immunity, vol. 29, no. 3, pp. 372–383, 2008. View at Publisher · View at Google Scholar · View at PubMed
  93. J. Banchereau, E. Klechevsky, N. Schmitt, R. Morita, K. Palucka, and H. Ueno, “Harnessing human dendritic cell subsets to design novel vaccines,” Annals of the New York Academy of Sciences, vol. 1174, pp. 24–32, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. S. J. Um, Y. J. Choi, H. J. Shin, et al., “Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer,” Lung Cancer. In press.
  95. L. J. Chang, “Lentiviral vector transduction of dendritic cells for novel vaccine strategies,” Methods in Molecular Biology, vol. 614, pp. 161–171, 2010.
  96. H. S. Kim, C. H. Kim, M. Y. Park, et al., “Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and surviving into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model,” Immunology Letters. In press. View at Publisher · View at Google Scholar · View at PubMed
  97. U. Winters, S. Daayana, J. T. Lear, et al., “Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia,” Clinical Cancer Research, vol. 14, no. 16, pp. 5292–5299, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. G. Gausdal, B. T. Gjertsen, E. McCormack, et al., “Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death,” Blood, vol. 111, no. 5, pp. 2866–2877, 2008. View at Publisher · View at Google Scholar · View at PubMed
  99. R. Houot, M. J. Goldstein, H. E. Kohrt, et al., “Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion,” Blood, vol. 114, no. 16, pp. 3431–3438, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. O. Bruserud, E. Ersvær, A. Olsnes, and B. T. Gjertsen, “Anticancer immunotherapy in combination with proapoptotic therapy,” Current Cancer Drug Targets, vol. 8, no. 8, pp. 666–675, 2008. View at Publisher · View at Google Scholar
  101. A. M. Carella, N. Pollicardo, E. Pungolino, et al., “Mobilization of cytogenetically ‘Normal’ blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia,” Leukemia and Lymphoma, vol. 9, no. 6, pp. 477–483, 1993.
  102. J. C. Wojciechowski, S. D. Narasipura, N. Charles, et al., “Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device,” British Journal of Haematology, vol. 140, no. 6, pp. 673–681, 2008. View at Publisher · View at Google Scholar · View at PubMed
  103. S. P. Huck, S.-C. Tang, K. A. Andrew, J. Yang, J. L. Harper, and F. Ronchese, “Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors,” Cancer Immunology, Immunotherapy, vol. 57, no. 1, pp. 63–71, 2008. View at Publisher · View at Google Scholar · View at PubMed
  104. R. Houot and R. Levy, “Vaccines for lymphomas: idiotype vaccines and beyond,” Blood Reviews, vol. 23, no. 3, pp. 137–142, 2009. View at Publisher · View at Google Scholar · View at PubMed
  105. H. Wagner, “The immunogenicity of CpG-antigen conjugates,” Advanced Drug Delivery Reviews, vol. 61, no. 3, pp. 243–247, 2009. View at Publisher · View at Google Scholar · View at PubMed
  106. J. M. Roda, R. Parihar, and W. E. Carson III, “CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells,” Journal of Immunology, vol. 175, no. 3, pp. 1619–1627, 2005.
  107. M. J. Flaminio, A. S. Borges, D. V. Nydam, D. W. Horohov, R. Hecker, and M. B. Matychak, “The effect of CpG-ODN on antigen presenting cells of the foal,” Journal of Immune Based Therapies and Vaccines, vol. 5, article 1, 2007. View at Publisher · View at Google Scholar · View at PubMed
  108. J. Vollmer and A. M. Krieg, “Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists,” Advanced Drug Delivery Reviews, vol. 61, no. 3, pp. 195–204, 2009. View at Publisher · View at Google Scholar · View at PubMed
  109. M. Ferrantini, I. Capone, and F. Belardelli, “Dendritic cells and cytokines in immune rejection of cancer,” Cytokine and Growth Factor Reviews, vol. 19, no. 1, pp. 93–107, 2008. View at Publisher · View at Google Scholar · View at PubMed
  110. A. Perez-Garcia, S. Brunet, J. J. Berlanga, et al., “CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy,” Leukemia, vol. 23, no. 3, pp. 486–491, 2009. View at Publisher · View at Google Scholar · View at PubMed
  111. A. Reichle and G. C. Hildebrandt, “Principles of modular tumor therapy,” Cancer Microenvironment, vol. 2, supplement 1, pp. S227–S237, 2009. View at Publisher · View at Google Scholar · View at PubMed
  112. A. Dimberg, “Chemokines in angiogenesis,” Current Topics in Microbiology and Immunology. In press.
  113. Y. Nakazaki, H. Hase, H. Inoue, et al., “Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses,” Molecular Therapy, vol. 14, no. 4, pp. 599–606, 2006. View at Publisher · View at Google Scholar · View at PubMed
  114. S. Song, C. Liu, J. Wang, et al., “Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect,” Vaccine, vol. 27, no. 7, pp. 1111–1118, 2009. View at Publisher · View at Google Scholar · View at PubMed
  115. N. Lapteva, M. Aldrich, D. Weksberg, et al., “Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity,” Journal of Immunotherapy, vol. 32, no. 2, pp. 145–156, 2009. View at Publisher · View at Google Scholar · View at PubMed
  116. E. M. Borroni, A. Mantovani, M. Locati, and R. Bonecchi, “Chemokine receptors intracellular trafficking,” Pharmacology & Therapeutics. In press.
  117. X. Zang and J. P. Allison, “The B7 family and cancer therapy: costimulation and coinhibition,” Clinical Cancer Research, vol. 13, no. 18, pp. 5271–5279, 2007. View at Publisher · View at Google Scholar · View at PubMed
  118. J. Rosenblatt, Z. Wu, B. Vasir, et al., “Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28,” Journal of Immunotherapy, vol. 33, no. 2, pp. 155–166, 2010. View at Publisher · View at Google Scholar · View at PubMed
  119. R. Elgueta, M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle, “Molecular mechanism and function of CD40/CD40L engagement in the immune system,” Immunological Reviews, vol. 229, no. 1, pp. 152–172, 2009. View at Publisher · View at Google Scholar · View at PubMed
  120. H. J. Stauss, M. Cesco-Gaspere, S. Thomas, et al., “Monoclonal t-cell receptors: new reagents for cancer therapy,” Molecular Therapy, vol. 15, no. 10, pp. 1744–1750, 2007. View at Publisher · View at Google Scholar · View at PubMed
  121. H. J. Stauss, S. Thomas, M. Cesco-Gaspere, et al., “WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells,” Blood Cells, Molecules, and Diseases, vol. 40, no. 1, pp. 113–116, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harrington, “IL-17 family cytokines and the expanding diversity of effector T cell lineages,” Annual Review of Immunology, vol. 25, pp. 821–852, 2007. View at Publisher · View at Google Scholar · View at PubMed
  123. S. L. Gaffen, J. M. Kramer, J. J. Yu, and F. Shen, “The IL-17 cytokine family,” Vitamins and Hormones, vol. 74, pp. 255–282, 2006. View at Publisher · View at Google Scholar · View at PubMed
  124. Y. Bi, G. Liu, and R. Yang, “Th17 cell induction and immune regulatory effects,” Journal of Cellular Physiology, vol. 211, no. 2, pp. 273–278, 2007. View at Publisher · View at Google Scholar · View at PubMed
  125. I. Kryczek, S. Wei, L. Zou, et al., “Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment,” Journal of Immunology, vol. 178, no. 11, pp. 6730–6733, 2007.
  126. N. Hirahara, Y. Nio, S. Sasaki, et al., “Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice,” Oncology, vol. 61, no. 1, pp. 79–89, 2001. View at Publisher · View at Google Scholar
  127. M. C. Honorati, S. Neri, L. Cattini, and A. Facchini, “IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis,” Clinical and Experimental Immunology, vol. 133, no. 3, pp. 344–349, 2003. View at Publisher · View at Google Scholar
  128. S. Sakaguchi, “Naturally arising foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self,” Nature Immunology, vol. 6, no. 4, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at PubMed
  129. A. M. Gallegos and M. J. Bevan, “Central tolerance: good but imperfect,” Immunological Reviews, vol. 209, pp. 290–296, 2006. View at Publisher · View at Google Scholar · View at PubMed
  130. J. Shimizu, S. Yamazaki, and S. Sakaguchi, “Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity,” Journal of Immunology, vol. 163, no. 10, pp. 5211–5218, 1999.
  131. M. Beyer, M. Kochanek, K. Darabi, et al., “Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine,” Blood, vol. 106, no. 6, pp. 2018–2025, 2005. View at Publisher · View at Google Scholar · View at PubMed
  132. F. Ghiringhelli, N. Larmonier, E. Schmitt, et al., “CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative,” European Journal of Immunology, vol. 34, no. 2, pp. 336–344, 2004. View at Publisher · View at Google Scholar · View at PubMed
  133. S. Audia, A. Nicolas, D. Cathelin, et al., “Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes,” Clinical and Experimental Immunology, vol. 150, no. 3, pp. 523–530, 2007. View at Publisher · View at Google Scholar · View at PubMed
  134. Y. Qu, B. Zhang, L. Zhao, et al., “The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+foxp3+T cells in mice,” Transplant Immunology, vol. 17, no. 3, pp. 153–161, 2007. View at Publisher · View at Google Scholar · View at PubMed
  135. C. T. Garnett, J. Schlom, and J. W. Hodge, “Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement,” Clinical Cancer Research, vol. 14, no. 11, pp. 3536–3544, 2008. View at Publisher · View at Google Scholar · View at PubMed
  136. M. J. Szczepanski, M. Szajnik, M. Czystowska, et al., “Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia,” Clinical Cancer Research, vol. 15, no. 10, pp. 3325–3332, 2009. View at Publisher · View at Google Scholar · View at PubMed
  137. E. M. Eisenstein and C. B. Williams, “The Treg/Th17 cell balance: a new paradigm for autoimmunity,” Pediatric Research, vol. 65, pp. 26R–31R, 2009. View at Publisher · View at Google Scholar · View at PubMed